0000000000540060

AUTHOR

F De Arriba

showing 2 related works from this author

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered ce…

2011

Disappearance of normal bone marrow (BM) plasma cells (PC) predicts malignant transformation of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) into symptomatic multiple myeloma (MM). The homing, behavior and survival of normal PC, but also CD34 hematopoietic stem cells (HSC), B-cell precursors, and clonal PC largely depends on their interaction with stromal cell-derived factor-1 (SDF-1) expressing, potentially overlapping BM stromal cell niches. Here, we investigate the distribution, phenotypic characteristics and competitive migration capacity of these cell populations in patients with MGUS, SMM and MM vs healthy adults (HA) aged 60 years. Our result…

AdultMalemalignant transformationCancer ResearchPathologymedicine.medical_specialtyStromal cellPlasma CellsParaproteinemiasCD34Bone Marrow CellsEnzyme-Linked Immunosorbent AssayBiologyplasma cellsImmunophenotypingImmunophenotypingCell Movementhemic and lymphatic diseasesmedicineHumansProspective StudiesCells CulturedMultiple myelomaAgedAged 80 and overB-Lymphocytesmonoclonal gammopathiesbone marrow niche competitionHematologyMiddle AgedFlow CytometryHematopoietic Stem Cellsmedicine.diseaseClone CellsHaematopoiesisLeukemiamedicine.anatomical_structureOncologyCase-Control StudiesCancer researchFemaleBone marrowMultiple MyelomaMonoclonal gammopathy of undetermined significanceLeukemia
researchProduct

Matched-pairs analysis of outcomes with bortezomib, melphalan, and prednisone (VMP) treatment for previously untreated multiple myeloma (MM) using lo…

2015

(95% CI: 58-88%), respectively. A formal interim analysis of the Day 90 CR rate was conducted when 65 patients were evaluable, and at that time the Mel only arm was determined to be superior. The study was, therefore, stopped early by the Institutional DSMB. However, with a longer follow up Bu-Mel ultimately resulted in better PFS. Conclusions: Bu-Mel was associated with a significantly lower day 90 CR rate and a significantly higher rate of grade 3-4 non-hematologic toxicity, compared to Mel. However, after a median follow up of 15.7 months, PFS was significantly longer in the Bu-Mel arm. Figure 1 PFS from Day 90 by Treatment Arm

MelphalanCancer Researchmedicine.medical_specialtyLong term follow upbusiness.industryBortezomibUrologyHematologyInterim analysismedicine.diseasecarbohydrates (lipids)OncologyPrednisoneMedian follow-uphemic and lymphatic diseasesToxicitymedicinebusinessneoplasmsMultiple myelomamedicine.drugClinical Lymphoma Myeloma and Leukemia
researchProduct